The biosimilar contract manufacturing market is projected to grow from USD 8.9 billion in 2025 to USD 32.7 billion by 2035, at a CAGR of 13.9%. Mammalian will dominate with a 58.0% market share, while recombinant non-glycosylated proteins will lead the service outlook segment with a 55.2% share.